Prostacyclin and thromboxane in benign and malignant breast tumours. by Laekeman, G. M. et al.
Br. J. Cancer (1986) 54, 431-437
Prostacyclin and thromboxane in benign and malignant
breast tumours
G.M. Laekeman', I.B. Vergote2, G.M. Keersmaekers2, J. Heiremans1,
C.F. Haensch2, G. de Roy2, F.L. Uyttenbroeck2 & A.G. Herman'
1Division of Pharmacology and 2Department of Gynecology and Obstetrics, and Pathology, St. Camillus
Hospital, University ofAntwerp, Universiteitsplein, 1, B2610 Wilrijk, Belgium.
Summary 6-keto-PGFi,, and thromboxane B2 were determined by radioimmunoassay in 37 extracts of
breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More
prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-
disease tissues (P<0.05). The 6-keto-PGF1./TXB2 ratio was higher in carcinomata than in normal tissues and
fibroadenomata (P<0.05) but was not significantly different from the ratio in sclerocystic disease. The
prostaglandin levels and the 6-keto-PGF1./TXB2 ratios from carcinomata did not correlate significantly with
age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells,
necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-
PGF1,/TXB2 ratios (P=0.01) whereas the latter value was higher when infiltration was lower (P=0.03).
There was a positive correlation between mitotic index and the 6-keto-PGF1./TXB2 ratio (P=0.04).
Cumulation of variables revealed lower prostanoid ratios in tumours >2cm without lymph node metastasis
then tumours <2cm with lymph node metastasis (P=0.05). A first follow-up (14 months) showed a higher 6-
keto-PGF1./TXB2 ratio in patients who developed metastasis (P=0.04). Our study does not confirm the
hypothesis that high prostacyclin levels are a good prognostic index in breast cancer.
Honn et al. (1981) found that prostacyclin (PGI2)
had a beneficial influence against metastasis of B16
amelanotic melanoma tumours in mice, whereas
inhibitors of PGI2 synthesis enhanced the number
of metastases. Other authors tested the antimeta-
static potency of acetylsalicylic acid, indomethacin,
dipyridamole, flurbiprofen, benorylate, heparin and
warfarin (Gasic et al., 1973; Elias et al., 1973;
Lione & Bosman, 1978; Bennett, 1982). Most of
these studies are done on animals and showed no
clearcut results.
Thromboxane (TX) A2 is often a physiological
antagonist of PGI2 and an imbalance between them
can disturb the (anti)haemostatic system. The anti-
aggregating properties of nonsteroidal anti-
inflammatory drugs (NSAID) can be explained by
a stronger inhibition of the platelet cyclo-oxygenase
in comparison with that of the vessel wall. As a
result the release of TX will be lowered and aggre-
gation will be blocked (Bunting et al., 1983). Sloane
et al. (1981) showed that some tumours are able to
release cathepsin B. This enzyme stimulates the
synthesis of TX and is produced in a variant of B16
melanoma which has high metastatic activity.
In order to study a possible prognostic value of
the PGI2/TX ratio in breast cancer, the stable
hydrolysis products of PGI2 (6-keto-PGF1,) and
TXA2 (TXB2) were determined by RIA. 6-keto-
PGF1, and TXB2 levels were examined in relation
to the size of the tumour, axillary lymph node
status, lymphatic vessel permeation, differentiation
of the tumour, mitotic index density of nuclei of
tumour cells, and age of the patient.
PG production can be influenced by inflam-
matory processes (Humes et al., 1977; Brune et al.,
1978), and therefore the number of host-derived
cells and the amount of necrosis was evaluated.
Also the density of blood vessels was estimated as
they could be a major source of 6-keto-PGF1.
(Moncada et al., 1976), and platelets contribute
considerably to the amounts of TXB2 measured
(Hamberg et al., 1975).
Materials and methods
We obtained 108 specimens from 67 patients who
underwent surgery for a breast lump. Each speci-
men was divided into two representative parts and
prepared as described earlier by Vergote et al.
(1985). The tissues were immediately immersed
either in acetone cooled by solid CO2 (- 70°C) for
6-keto-PGF1. or TXB2 analysis, or in Bouin's liquid
for histopathological examination. The tissue
samples for prostanoid investigation were stored at
-30°C until radioimmunoassay was performed.
t The Macmillan Press Ltd., 1986
Correspondence: G.M. Laekeman
Received 8 November 1985; and in revised form 23 April
1986.432 G.M. LAEKEMAN et al.
Thirty-five tumours were diagnosed as primary
breast cancer (patient age range: 36-82; mean 64).
The patients were classified according to the
pathological TNM system (UICC, Livre de Poche),
pTlaNo 9; pTlaNla 1; pTlaNlb 4; pTlaNx 2;
pT2aNo 4; pT2aNla 2; pT2aNlb 4; pT2aNx 2;
pT3aNo 2; pT4bNx 1. No patient had overt meta-
stases at the time of surgery and none was under
current treatment with non-steroidal inflammatory
drugs or corticosteroids. Five local relapses (ductal
carcinomata) and one cellular intracanicular fibro-
adenoma were included. Twenty tumours were
benign: 8 fibroadenomata (age range: 17-47, mean:
34) and 12 sclerocystic-disease specimens (age
range: 37-70, mean: 49). We investigated also histo-
logically confirmed normal breast tissue of patients
with malignant tumours and fibroadenomata.
Furthermore, 12 specimens of patients who had
neither benign nor malignant tumours were studied.
The age of the patients and the tumour size at
anatomopathological examination were recorded.
The amounts of 6-keto-PGF1. and TXB2 were
expressed as ngmg-1 protein and from these values
the 6-keto-PGF1./TXB2 ratio was calculated.
Histopathology
The slides were independently reviewed by two of
the authors and re-evaluated by a senior path-
ologist. In case of discordance, the results were not
included in this study.
Tumours were classified according to the
methodology used earlier (Vergote et al., 1985).
Subdivision of histopathological variables is shown
in Table III.
Radioimmunoassay (RIA)
For the extraction of prostaglandins and the pro-
tein measurement the procedure of Vergote et al.
(1985) was used. Acetone was evaporated under
nitrogen and the weight of the tissue determined.
Tris buffer (50mM, pH = 8.0 at 25°C) was added
(3mlg-' tissue) and sonicated for 90min
(Bransonic). Ice was regularly added to the bath
fluid. The supernatant was separated from the tissue
after centrifugation at 1O,OOOg (Eppendorf centri-
fuge). RIA was performed directly on the super-
natant according to Granstrom and Kindahl (1978).
The antisera were raised in rabbits. Cross reactivi-
ties on the 50% binding level of the curve were: for
the 6-keto-PGF1.-antiserum: PGF1l,, 1%; 15-HETE
(hydroxyeicosatetraenoic acid), 0.01%; 15-HPETE
(hydroperoxyeicosatetraenoic acid), 0.01%; PGE2,
15-keto-PGE2, TXB2 and AA (arachidonic acid)
<0.01%; for the TXB2 antiserum: PGD2, 8.9%;
PGF20, 1%; PGE2, 0.9%; 6-keto-PGFJ,. 0.1%; 15-
keto-13,14-dihydro-PGF2., AA, 15-HETE and 15-
HPETE, <0.01%.
The extraction recoveries for 6-keto-PGF1a were
112+10% (mean +SE: n=3) and for TXB2
97+16 (mean + SE; n=3). The intra-assay varia-
tion coefficient for RIA of6-keto-PGF1. and TXB2
were 15+1% (n= 103) and 13+1% (n=111)
respectively.
Reagents
TXB2 and 6-keto-PGF1. (Upjohn), (3H)-radio-
labelled 6-keto-PGF1. and (3H)-TXB2 (NEN). Tris
buffer was made with trizma base (Sigma) and HCI
(Merk p.a.).
Statistical analysis
Nonparametric statistical canalysis was used to
compare two (Wilcoxon test) or more groups
(Kruskal & Wallis test; Sokal & Rohlf, 1981).
Correlation coefficients were calculated by linear
regression.
Results
PG levels in relation to the histopathological groups
6-keto-PGF1a levels were higher in carcinomata
(CA) than in normal breast tissue (N), fibro-
adenomata (FA) and sclerocystic disease (SCD)
(P=0.0003, Kruskal & Wallis). In FA, N and SCD
the levels did not differ significantly (P=0.17,
Kruskal & Wallis). CA-TXB2 levels were signifi-
cantly higher in comparison with the other groups
(P=0.05, Kruskal & Wallis). The differences between
N, FA and SCD were not significant (P=0.83,
Kruskal & Wallis). The 6-keto-PGF1J/TXB2 ratio
in CA was higher than in N and FA (P=0.002,
Kruskal & Wallis) which were similar (P=0.39).
SCD and CA also gave similar ratios (P=0.67).
These results are summarized in Table I and Figure
1. When local relapses (n=5) were calculated
separately, 6-keto-PGF1,, TXB2 and the 6-keto-
PGF1./TXB2 ratio were respectively, median (limit
values): 12.7 (0.6-15.0) ngmg-1 protein, 2.5 (1.8-
3.4) ngmg-1 protein and 4.0 (0.3-7.3). They were
similar to the ductal carcinomata (P= 0.95; P=0.40
and P=0.28 respectively).
Histological type and differentiation
The infiltrating ductal carcinomata composed the
substantial group. Statistical comparison between
all the groups was difficult because some contained
very few cases (Table II). We divided the tumours
into two groups: undifferentiated and some degree
of differentiation (small, noderate or high). BothPGI2 AND TXB2 IN BREAST CANCER 433
Table I PG-levels in relation to the pathology
ng 6-keto-PGF1.mg1 ng TXB2 mg-1
protein protein 6-keto-PGF1J/TXB2
median median median
Pathology n (semiquartiles) (semiquartiles) (semiquartiles)
CA 37 4.4 (1.7-14.3) 0.6 (0.4-2.8) 4.6 (3.2-9.2)
N 51 1.2 (0.4-3.3) 0.4 (0.2-0.8) 2.6 (1.4-5.2)
FA 8 0.3 (0.2-1.8) 0.4 (0.2-0.5) 1.8 (0.7-4.9)
SCD 12 1.7 (0.9-3.5) 0.4 (0.2-1.0) 4.3 (2.7-8.7)
CA=carcinomata; N=normals; FA fibroadenomata; SCD sclerocystic disease.
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Figure 1 Individual 6-keto-PGF1,/TXB2 values in the pathological groups: CA (n=37; carcinomata), N
(n=51; normal breast tissue), FA (n=8; fibroadenomata), SCD (n=12; sclerocystic disease). Medians and
semiquartiles are indicated.
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Table II PG-levels in relation to the histological type
Type n ng6-keto-PGF<,.mg protein ng TXB2mg1 protein 6-keto-PGFJ.ITXB2
Infiltrating ductal
carcinoma 23 4.4 (2.3-16.6)a 1.0 (0.3-3.4)a 4.6 (3.3-9.6)a
Lobular 2 5.1-8.1 0.4-0.5 12.8-15.2
Comedo 4 0.4-2.2 0.1-0.7b 0.6-8.33
Medullary 1 1.4 0.4 4.0
Mucoid 1 7.7 3.6 2.1
aMedian (semiquartiles); bLimit values434 G.M. LAEKEMAN et al.
groups showed similar 6-keto-PGF1,, TXB2 and 6-
keto-PGF1./TXB2 levels (Table III).
Lymph node metastasis and lymphatic vessel
permeation
The median amount of 6-keto-PGF1a was slightly
higher in tumour extracts from patients without
lymph node metastasis (P=0.23). Median TXB2
amounts and the 6-keto-PGF1a/TXB2 ratio were
comparable.
The groups without lymphatic vessel permeation
had more 6-keto-PGF1a (P=0.04), but the TXB2
values and the 6-keto-PGF1./TXB2 ratio were
similar (Table III).
Size and density ofnuclei ofcarcinoma cells
Tumours with moderate density had significantly
less 6-keto-PGF1, (P=0.04) and TXB2 (P=0.01)
than those with low or high density. Higher 6-keto-
PGF1,/TXB2 ratios were found in moderate and
high density groups (P=0.01; Table III).
Carcinomata with large nuclei tended to yield less
TXB2 than those having moderate size nuclei
(P=0.18; Table III).
Mitotic index
There was at most a weak correlation between the
number of mitoses per high power field (HPF) and
the 6-keto-PGF1 or TXB2 levels (r= -0.167,
P=0.18 and -0.212, P=0.13 respectively), but a
positive correlation occurred with the 6-keto-
PGF1./TXB2 ratio (r=0.33, P=0.04).
Nuclear and cellular polymorphism and the nuclear
cytoplasmic ratio
Tumours with a low nuclear and cellular poly-
morphism showed at most a weak tendency to
higher 6-keto-PGF1. levels (P=0.19) no other re-
lationships were seen.
Host cell reaction, necrosis and mast cells
Host cell reaction, necrosis and presence of mast
cells did not correlate with the amounts of
extracted prostanoids.
Elastosis,fibrosis and infiltration
No significant tendencies were observed between
PG-levels and elastosis or fibrosis. Infiltration was
inversely related to the 6-keto-PGFJT/TXB2 ratio
(P=0.03), but no significant differences were seen
for the 6-keto-PGF1. or TXB2 (Table III).
Blood vessel density
Presence of blood vessels did not correlate with
prostanoid yields in the tumour biopsies. the 6-
keto-PGF1./TXB2 ratio even tended to be lower
when more blood vessels were present (P=0.18;
Table III).
Age
No correlations between prostanoids and age were
seen: 6-keto-PGF1 , r= -0.023 (P=0.45), TXB2,
r=0.157 (P=0.20), 6-keto-PGF1./TXB2 r=0.179
(P=0.20).
Cumulation ofvariables andfollow up
Tumour size showed little or no relationship to
tissue prostanoids: 6-keto-PGF1, r= -0.182
(P=0.16), TXB2 r -0.126 (P=0.41), 6-keto-
PGFJ./TXB2 r= -0.038 (P=0.42). Tumours with
strong metastatic potential (<2cm and lymph node
metastasis, n=5) had a median 6-keto-
PGF1,/TXB2 ratio of 3.8 (2.0-9.4), which was
higher (P<0.05) than with tumours having a
relatively weak metastatic potential (>2 cm and no
lymph node metastasis, n =7; 2.8 (0.5-4,6)).
A preliminary analysis of 19 patients with a
follow-up of 14 months revealed metastases in 5
patients. These 5 patients had a median 6-keto-
PGF,,/TXB2 ratio of 9.2 (4.0-15.3) which was
higher than the ratio of nonmetastatic patients 4.8
(1.6-13.5) (P=0.04).
Discussion
Little is known about the role of PGI2 and TX in
human malignant tumours, and only 2 studies on
extracted breast tissues have been published.
Karmali et al. (1983) measured 6-keto-PGF1. and
TXB2 in 24 breast tumours and expressed their
results as log ngg-1 wet weight. They obtained
more TXB2 from large tumours and those with
lymph node metastasis. These results were
interpreted as supporting the findings of Honn
(1981) that a higher TXA2/PGI2 ratio has a worse
prognosis in terms of metastasis.
However, Karmali et al. (1983) did not give any
data about the 6-keto-PGF1./TXB2 ratio which is
important in the regulation of blood platelet ag-
gregation. Furthermore, the size of the tumour is
not necessarily an indication of the metastatic
potential. In addition, Karmali et al. (1983)
observed no correlation between TXB2 levels and
metastasis. Aitokallio-Tallberg et al. (1985) studied
the in vitro production of 6-keto-PGF1, and TXB2
by 23 breast tumour tissues, but as their investiga-
tions were directed towards steroid receptor statusPGI2 AND TXB2 IN BREAST CANCER 435
Table III Prostanoid levels and anatomopathological variables
ng 6-keto-PGF<,, ng TXB2 mg-1 6-keto-PGFia P
mg 1prot. prot. TXB2
median median median
Variable (n) (limit values) P (limit values) P (limit values)
Differentiation
no diff. (15)
diff. (16)
Lymph node metastasis
positive (11)
negative (15)
Lymphatic vessel permeation
positive (23)
negative (8)
Density of nuclei of
carcinoma cells
low (8)
moderate (16)
high (7)
Size of nuclei of
carcinoma cells
small (3)
moderate (23)
large (5)
Nuclear and cellular
polymorphism
low (8)
moderate (15)
high (8)
Nuclear cytoplasmic ratio
low (4)
moderate (20)
high (6)
Host cell reaction
low (19)
moderate (11)
Mast cells
positive (11)
negative (20)
Necrosis
positive (15)
negative (16)
Elastosis
positive (21)
negative (10)
Fibrosis
negative (2)
low (6)
moderate (16)
high (7)
Infiltration
low (3)
moderate (14)
high (14)
Blood vessel density
low (14)
moderate (8)
high (7)
5.0 (0.6-27.4)
4.4 (0.9-62.9)
3.9 (0.7-45.3)
5.4 (0.5-62.9)
4.0 (0.6-62.9)
9.3 (4.3-29.9)
0.44
0.23
0.04a
12.7 (1.4-62.9)
4.0 (0.6-16.7)
7.7 (2.2-27.4)
8.1 (0.6-14.3)
5.0 (0.9-27.4)
4.0 (1.2-8.3)
11.2 (0.6-62.9)
4.4 (0.9-29.9)
3.1 (1.2-8.3)
5.0 (1.2-16.6)
4.3 (0.9-62.9)
6.6 (0.6-24.6)
5.0 (0.6-62.9)
4.2 (1.0-27.4)
4.1 (1.2-62.9)
5.4 (0.6-29.9)
4.0 (1.2-26.5)
7.9 (0.6-62.9)
5.4 (1.4-62.9)
4.3 (0.6-27.4)
10.4-15.0
5.9 (0.6-8.3)
4.4 (1.2-62.9)
4.2 (0.9-29.9)
10.4 (1.7-15.0)
4.4 (0.9-26.5)
5.0 (0.6-62.9)
5.3 (0.9-29.9)
6.0 (1.2-27.4)
2.2 (0.6-62.9)
0.44
0.19
0.93
0.59
0.56
0.5 (0.1-17.0)
0.8 (0.1-12.8)
0.5 (0.3-6.5)
0.7 (0.1-12.8)
0.5 (0.1-17.0)
2.1 (0.3-9.6)
3.5 (0.4-12.8)
0.4 (0.1-2.7)
0.8 (0.3-17.0)
0.5 (0.2-1.8)
0.8 (0.1-17.0)
0.4 (0.3-0.9)
1.2 (0.2-17.0)
0.8 (0.1-11.2)
0.4 (0.3-3.6)
1.6 (0.3-3.6)
0.7 (0.1-17.0)
0.4 (0.2-5.3)
0.8 (0.1-12.8)
0.5 (0.2-17.0)
0.7 (0.3-12.8)
0.6 (0.1-17.0)
0.21 0.5 (0.1-11.2)
0.8 (0.1-17.0)
0.32 0.9 (0.2-12.8)
0.6 (0.1-17.0)
0.52 2.9-3.4
0.7 (0.3-1.8)
0.7 (0.1-17.0)
0.5 (0.1-9.6)
0.92 2.9 (0.4-3.4)
0.5 (0.1-11.2)
1.0 (0.2-17.0)
0.49 0.8 (0.1-9.6)
0.9 (0.3-17.0)
0.4 (0.2-12.8)
0.71 4.3 (0.3-17.5)
5.0 (2.4-14.4)
0.70 4.8 (2.8-10.0)
4.3 (1.8-9.2)
0.17 4.7 (0.3-17.5)
5.2 (3.1-15.2)
o.ola
0.18
0.44
0.74
0.39
0.77
0.59
0.57
0.40
0.49
0.38
2.9 (2.1-4.6)
6.1 (0.3-17.5)
7.0 (1.6-14.4)
7.7 (0.3-15.2)
4.4 (1.6-17.5)
9.7 (4.6-13.4)
5.1 (0.3-15.2)
4.4 (2.4-17.5)
4.9 (2.1-13.4)
4.9 (2.1-6.1)
4.2 (1.6-17.5)
5.1 (0.3-15.2)
4.0 (0.3-17.5)
5.1 (1.6-13.4)
4.6 (2.1-13.4)
5.1 (0.3-17.5)
4.8 (2.1-17.5)
4.4 (0.3-15.2)
5.1 (0.3-17.5)
3.2 (2.4-13.4)
3.6-4.4
9.4 (0.3-15.2)
4.6 (1.6-17.5)
8.1 (2.1-10.1)
4.4 (3.6-4.6)
8.0 (2.4-17.5)
3.2 (0.3-10.0)
8.0 (2.1-17.5)
3.7 (1.6-15.2)
4.8 (0.3-13.4)
aSignificantly different
0.68
0.89
0.53
o.ola
0.34
0.98
0.77
0.67
0.34
0.97
0.13
0.55
0.03*
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they did not include control tissue superfusion in
their protocol. The prostanoid yields were similar
from metastatized and non-metastatized cancers
(follow-up of at least 3 years).
We studied the PG-levels in the tumours at the
time of resection. Treatment with acetone at
-70°C inactivated the tumour enzymes and stopped
the conversion of arachidonic acid to prosta-
glandins (Vergote et al., 1985). Prostanoids were
measured in the tumour extracts, but the recoveries
were about 100%, we can consider the RIA-results
as reflecting the prostanoid production at the time
of resection. Since the surgical manipulation might
induce PGI2 and TXA2 production, we also
analyzed normal breast tissue taken from the neigh-
bourhood of the cancer. The tumour specimen was
always taken first, so that artefactual prostanoid
might be higher in the normal tissue because of the
longer trauma or lower because of prostanoid meta-
bolism. For example 6,15-diketo 13,14-dihydro
PGF,, is formed from PGI2 in plasma and vascular
tissue (Peskar et al., 1980).
However, continued enzymatic conversion would
be blocked by the acetone treatment.
Non-malignant sources of the tumour prosta-
noids are the host cells, but no correlation was
found between the amounts of the prostanoids and
the host cell reaction or the presence of mast cells.
Furthermore, the 6-keto-PGFJ and TXB2 tissue
levels did not correlate with the density of blood
vessels.
We preferred to express the prostanoid yields in
ngmg1 protein, rather than to use ngg- wet or
dry weight, in an attempt to reduce the variation of
the results. One of the main conclusions from our
study is that carcinomata had higher median 6-
keto-PGF1. and TXB2 levels than N, FA or SCD,
but even so, the ranges overlapped considerably.
As can be seen from Table III, most of the
differences were not significant, but a high meta-
static potential and mitotic index correlated with
higher 6-keto-PGF1J/TXB2 ratios. Furthermore,
with 42 comparisons, 2 would be expected by
chance to show P values <0.05 when no difference
really exists.
No firm conclusions can yet be made, although
follow-up over 14 months revealed a higher 6-keto-
PGFJ,/TXB2 ratio in patients with metastasis.
These data should be interpreted very cautiously, as
the number of patients evaluated is low and the
follow-up period is limited. Nevertheless, the histo-
pathology results do not support the suggestion of
Karmali et al. (1983), for a protective action of
prostacyclin against metastasis in human breast
cancer, or the hypothesis of Honn (1981) that
TXA2 promotes metastasis.
A common observation by several authors is the
greater prostaglandin production by malignant
breast tumours compared with normal breast
tissues. This conclusion is independent of the
prostaglandin measured or the ways of performitig
the incubations, extractions or measurements
(Bennett et al., 1975; Kibbey et al., 1979; Greaves
et al., 1980; Rolland et al., 1980; Malachi et al.,
1981; Campbell et al., 1983; Karmali et al., 1983).
The relationship between high prostaglandin levels
and malignancy of breast tumours could lead to the
systematic incorporation of cyclo-oxygenase inhibi-
tors (NSAID) in cancer therapy. However, when
histopathological prognostic variables of malignant
tissues are examined, the prognosis seems to be
better when the PGF2a levels were higher (Vergote
et al., 1985). Although this was not found for 6-
keto-PGF1 and TXB2 in our present study, the
mitotic index, prognosis and the first follow-up
results indicate that tumour 6-keto-PGF1 at the
time of surgery was often higher in patients with
bad prognosis or metastasis. Using NSAID could
theoretically worsen the prognosis, by depressing
the 6-keto-PGF1. levels, but we do not know what
effect this would have on the 6-keto-PGFJ,/TXB2
ratio. Therefore we can neither support nor
recommend the use of NSAID in the treatment of
breast cancer, particularly since other actions of
prostaglandins, e.g. in immunological functions,
may also be affected.
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